吉西他滨联合奥沙利铂或5氟尿嘧啶治疗晚期胰腺癌的临床应用  

Clinical study of gemcitabine combined with oxaliplatin or 5-fluorouracil in treatment of advanced pancreatic cancer

作　　者：柯珂[1] 余云熹 

机构地区：[1]湖北省黄石市中心医院湖北省理工学院附属医院肿瘤内科,黄石435000 [2]湖北省黄石市中医医院团城山院区内六科,黄石435000

出　　处：《中国肿瘤临床与康复》2016年第6期705-707,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的比较吉西他滨联合奥沙利铂或5氟尿嘧啶(5-Fu)治疗晚期胰腺癌的临床效果。方法选取2013年1月至2015年1月间在黄石市中心医院治疗的86例晚期胰腺癌患者,按随机数字表法分为奥沙利铂组和氟尿嘧啶组,每组43例。比较两组患者短期疗效、无进展生存时间、总生存时间和不良反应发生率。结果两组患者的近期疗效差异均无统计学意义(均P>0.05)。两组患者无进展生存时间和总生存时间差异均无统计学意义(均P>0.05)。氟尿嘧啶组患者并发症发生率显著高于奥沙利铂组,差异有统计学意义(P<0.05)。结论两种治疗方案均具有较好的临床治疗效果,但吉西他滨联合奥沙利铂的治疗方案不良反应更轻微,具有临床应用价值。Objective To compare the clinical differences of gemcitabine combined with oxaliplatin or 5-fluorouracil（ 5-FU） in treatment of advanced pancreatic cancer. Methods From January 2013 to January 2015 in Huangshi Centre Hospital,86 patients with advanced pancreatic cancer patients were randomly divided into uracil group and oxaliplatin group,43 cases in each group. The short-term efficacy,progression free survival,overall survival and adverse reactions of the two groups were compared. Results There was no significant difference in short-term efficacy between the two groups（ P〉 0. 05）. There was no significant difference in progression free survival and overall survival between the two groups（ P〉 0. 05）. The incidence of complications in uracil group was significantly higher than that in oxaliplatin group（ P 〈0. 05）.Conclusion Both treatment has well clinical curative effects,but the adverse reaction of gemcitabine combined with oxaliplatin treatment was more moderate,has the value of clinical application.

关 键 词：胰腺肿瘤 药物疗法 治疗结果 

分 类 号：R735.9[医药卫生—肿瘤]